Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in stock price and trading volume on January 9, 2025 [1] - On January 9, Jiuzhou Pharmaceutical's stock price increased by 3.18%, with a trading volume of 465 million yuan. The net financing purchase was 5.38 million yuan, indicating strong investor interest [1] - As of January 9, the total margin balance for Jiuzhou Pharmaceutical was 489 million yuan, with financing accounting for 2.82% of the circulating market value, which is above the 60th percentile of the past year [1] Group 2 - As of September 30, 2025, Jiuzhou Pharmaceutical reported a total revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92%, and a net profit attributable to shareholders of 748 million yuan, up 18.51% year-on-year [2] - The company has distributed a total of 2.18 billion yuan in dividends since its A-share listing, with 1.25 billion yuan distributed in the last three years [3] - The number of shareholders increased to 59,200, with an average of 15,035 circulating shares per person, a decrease of 9.27% from the previous period [2]

Core Viewpoint - Jiuzhou Pharmaceutical announced that its wholly-owned subsidiary, Zhejiang Ruibo Pharmaceutical Co., Ltd., has been recognized as a high-tech enterprise, which may enhance its competitive position and innovation capabilities in the pharmaceutical industry [2]. Group 1 - The announcement was made on January 9, indicating the company's proactive approach to innovation and technology [2]. - The certification was issued by the National High-tech Enterprise Recognition Management Work Leading Group Office, highlighting the credibility of the recognition process [2]. - The certificate number is GR202533010708, with an issuance date of December 19, 2025, and a validity period of three years [2].

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Zhejiang Ruibo Pharmaceutical Co., Ltd., has been recognized as a high-tech enterprise, which will allow the company to benefit from tax incentives for the next three years [1] Group 1 - Zhejiang Ruibo Pharmaceutical has received the high-tech enterprise certification with certificate number GR202533010708, issued on December 19, 2025, and valid for three years [1] - The company will enjoy a reduced corporate income tax rate of 15% from 2025 to 2027 due to its high-tech enterprise status [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Zhejiang Ruibo Pharmaceutical Co., Ltd., has been recognized as a high-tech enterprise, which will allow the company to benefit from tax incentives for the next three years [1] Group 1 - Zhejiang Ruibo Pharmaceutical Co., Ltd. received the high-tech enterprise certification with certificate number GR202533010708, issued on December 19, 2025, and valid for three years [1] - The company will enjoy a reduced corporate income tax rate of 15% from 2025 to 2027 due to its high-tech enterprise status [1]

浙江九洲药业股份有限公司 关于全资子公司获得高新技术企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据全国高新技术企业认定管理工作领导小组办公室于近日发布的《对浙江 省认定机构 2025 年认定报备高新技术企业进行备案的公告》，浙江九洲药业股份 有限公司（以下简称"公司"）全资子公司浙江瑞博制药有限公司（以下简称"浙 江瑞博"）已通过高新技术企业认定，证书编号为 GR202533010708，发证时间为 2025 年 12 月 19 日，有效期为三年。 证券代码：603456 证券简称：九洲药业 公告编号：2026-001 根据国家相关规定，浙江瑞博自通过高新技术企业认定后三年内（2025 年 至 2027 年）将享受国家关于高新技术企业的税收优惠政策，即按 15%的税率缴 纳企业所得税。 特此公告。 浙江九洲药业股份有限公司 董事会 2026 年 1 月 10 日 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456) acknowledges that its stock performance is influenced by multiple factors, including market conditions and sector rotation, while actively communicating its core value to the capital market [1] Group 1 - The company has implemented a new round of share buybacks, cancellation of treasury shares, and mid-term dividends this year [1]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is investing in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) through its wholly-owned subsidiary, with a total investment amount of RMB 77 million, of which Jiuzhou's contribution is RMB 10 million, accounting for 12.987% of the total [2][4]. Investment Overview - The investment is aimed at sectors related to new drug development and medical device research, focusing on high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research [2][12]. - The total subscribed capital of the partnership is RMB 77 million, which includes Jiuzhou's investment [4][12]. Partnership Agreement Details - The partnership agreement involves multiple partners, including Shihezi Longtai Equity Investment Management Partnership (Limited Partnership) and others, with Jiuzhou's subsidiary as a limited partner [4][5]. - The partnership has a duration of 6 years, with an investment period of 1.5 years and an exit period of 4.5 years [14]. - The management fee is set at 2% per year based on the total paid-in capital, with no management fee during the extension period [17]. Financial Impact and Strategic Alignment - This investment aligns with the company's overall development strategy and aims to leverage the expertise of professional investment management institutions to expand investment channels and generate returns [21]. - The investment is not expected to have a significant impact on the company's financial and operational status, complying with relevant laws and regulations [21].

证券代码：603456 证券简称：九洲药业 公告编号：2025-075 浙江九洲药业股份有限公司 关于全资子公司参与投资嘉兴隆峰创业投资合伙 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、对外投资概述 2025 年 12 月 22 日，公司全资子公司宏洲投资与石河子市隆泰股权投资管 理合伙企业（有限合伙）（以下简称"隆泰投资"）、嘉兴华锐贰号股权投资合伙 投资标的名称：嘉兴隆峰创业投资合伙企业（有限合伙）（以下简称"合 伙企业"） 投资金额：合伙企业认缴出资总额为人民币 7,700 万元（包含本次投资）， 浙江九洲药业股份有限公司（以下简称"公司"）全资子公司浙江宏洲 股权投资有限公司（以下简称"宏洲投资"）作为有限合伙人以自有资 金认缴出资额为人民币 1,000 万元，占合伙企业认缴出资总额的 12.987%。 投资方向：主要投资于新药研发、医疗器械研发项目等医药相关领域， 主要包括优质的新兴医疗企业，包括但不限于新药、创新药、医疗器械、 医疗服务、诊断、生物技术、医药外包研发企业等。 本次交易不构成关 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced its subsidiary Hongzhou Investment's participation in a partnership to invest in Jiaxing Longfeng Venture Capital Partnership, focusing on the pharmaceutical sector, particularly in new drug and medical device development [1] Investment Details - The total committed capital for the partnership is RMB 77 million, with Hongzhou Investment contributing RMB 10 million, representing 12.987% of the total [1] - The investment will primarily target high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Hongzhou Investment, plans to invest in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) with a total subscription amount of 77 million yuan, where Hongzhou Investment will contribute 10 million yuan, accounting for 12.987% of the total subscription amount [1] Group 1: Investment Details - The total subscription amount for the partnership is 77 million yuan, which includes this investment [1] - Hongzhou Investment will act as a limited partner and will contribute 10 million yuan of its own funds [1] - Hongzhou Investment's contribution represents 12.987% of the total subscription amount for the partnership [1] Group 2: Investment Focus - The partnership will primarily invest in new drug research and development, as well as medical device research projects within the pharmaceutical sector [1] - Investment targets include high-quality emerging medical enterprises, which encompass new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development companies [1]